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ABSTRACT 
Introduction: Lysosomal storage disorders (LSD) are 
inherited diseases caused, in the majority of them, by 
the deficiency of lysosomal enzymatic activities. Ob-
jectives: We aimed to analyze the usefulness of DBS 
samples for diagnosis of 4 LSDs, with the availability 
of a large quantity of patient samples. Design and 
methods: Blood samples from previously diagnosed 
patients with Fabry, Gaucher, Hunter, and Maro-
teaux-Lamy syndromes and normal control indi-
viduals, were collected and dispen-sed in filter paper, 
and used for enzymatic activity determination. Re-
sults: Diagnosis of hemi/homo-zygous patients with 
Fabry, Hunter and Maroteaux-Lamy diseases using 
DBS samples showed ideal parameters of 100% sen-
sitivity and specificity. DBS assay for Gaucher dis-
ease would need a posterior confirmatory step. Con-
clusions: Leukocyte measu-rement is the only reli-
able way to diagnose Gaucher disease. For Hunter, 
Fabry and Maroteaux-Lamy disorders discrimina-
tion between patients and controls seems adequate 
by DBS. 
Keywords: Lysosomal Storage Disorders; Diagnosis; 
Dried Blood Spots; Sensitivity; Enzymatic Activity; Re- 
liability 
1. INTRODUCTION 
Lysosomal storage disorders (LSD) are severe inherited 
diseases caused, in the majority of them, by the defi- 
ciency of lysosomal enzymatic activities, resulting in the 
accumulation of specific substances, such as complex 
lipids, glycoproteins and glycosaminoglycans. Clinical 
manifestations are characterized by a spectrum of clini- 
cal manifestations, which may include organ dysfunction, 
neurological involvement and skeletal abnormalities [1]. 
Enzyme replacement therapy is now available for speci-
fictreatment of 6 LSD, and is on development or in use 
in clinical trials for some others [2]. Early instauration of 
therapy, before irreversible organ damage, is needed for 
its better success. Therefore, early diagnosis is crucial. 
Diagnosis process generally starts by clinical suspi- 
cion by a physician [3]. However, due to age at onset of 
signs and symptoms is variable, and clinical manifesta- 
tions could be unspecific and multisystemic, LSD are 
generally underdiagnosed and/or there could be a sub- 
stantial delay between age at onset of manifestations and 
age at diagnosis. 
Diagnosis is confirmed by laboratory determination of 
the specific enzymatic activity in leukocytes or culture 
fibroblasts, using 4-methylumbelliferone conjugated ar- 
tificial substrate. The use of leukocytes as the enzyme 
source implies the isolation of these cells from a volume 
(10 mL) of liquid blood, requires a homogenisation step 
with a metal tip sonicator, and total protein measurement 
[4]. On the other hand, the use of fibroblasts requires a 
sample of skin biopsy, primary cell culture of skin fibro- 
blasts (avoiding the high risk of contamination), and to 
wait for the growing of fibroblasts to obtain enough cell 
counts [5]. 
Measurement of lysosomal enzymes activities in dried 
blood spots (DBS) on filter paper was introduced in 
2001 [6] as a method with several advantages over test- 
ing in leukocytes/fibroblasts. First, it requires only a few 
drops of blood. Second, the main benefit is the possibili- 
ty to mail the DBS samples to specialized laboratories, 
making it possible to send samples to other cities, re- 
gions or countries for testing. This is especially impor- 
tant due to LSD laboratory diagnosis is currently under- 
gone in specialized reference laboratories. Therefore 
there are a few labs per country, or somewhere they are 
missing. Finally, this method allows microplate adapta- 
tion, permitting the simultaneously measurement of mul- 
tiple samples and automation. Potentially, it could also 
be applicable to newborn screening. 
Due to different techniques of blood sample collection 
could change the enzyme activity, specific lab recom- 
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mendations for collection should be follow [7], in terms 
of the specific filter paper and use or not of anticoagu- 
lant. 
The usefulness of DBS for LSD diagnosis is not uni- 
versally accepted by medical community. Generally, 
physicians recommend assaying enzymatic activity in 
leukocytes/fibroblasts in order to confirm an abnormal 
result in DBS [8]. However, to our knowledge, there is 
no study analyzing clinical parameters of efficacy of en- 
zymatic activity determination on DBS for diagnosis of 
the lysosomal storage disorders Fabry, Gaucher, Hunter 
(Mucopolysaccharidosis II) and Maroteaux-Lamy (Mu- 
copolysaccharidosis VI). For this reason, we aimed to 
analyze the usefulness of DBS samples for diagnosis of 
these 4 LSDs, with the availability of a large quantity of 
patient samples. 
2. MATERIALS AND METHODS 
2.1. Patients and Samples 
Samples from previously diagnosed patients with Fabry 
(n = 45), Gaucher (n = 30), Hunter (n = 85), and Maro- 
teaux-Lamy(n = 22) diseases and normal control indi- 
viduals (n = 155), were obtained for this study. All the 
samples were taken before instauration of any specific 
treatment. Samples from heterozygous Fabry (n = 59), 
Hunter (n = 10) and Gaucher (n = 33) individuals were 
also included. The protocol was approved by the scien- 
tific committee of AADELFA according to provisions of 
the Declaration of Helsinki in 1995. The nature and pur- 
pose of the study and its possible risks were explained to 
all volunteers. All the patients gave their informed con- 
sent previous to the participation in the study. 
Peripheral blood samples were collected by venopun- 
cture, no anticoagulant was added. Immediatly, 50ul 
drops were dispensed in circles of S & S nº903 filter 
paper cards (Schleier and Schuell, Dassel, Germany). 
The cards were allowed to dry for 4 hours at room tem- 
perature. 
In order to control sample quality a reference enzyme 
was assayed in all DBS samples prior to the specific 
enzyme test. The chosen reference enzyme was beta- 
galactosidase (BGL1, EC 3.1.2.23), and was carried out 
according to the method of Civallero et al. [9]. All the 
samples showed normal values on BGL1 assay (data not 
shown), confirming the good quality of the samples ana- 
lyzed in this work. 
2.2. Enzymatic Activity Determination 
The determination of the enzymatic activities in DBS 
samples specific for each of the 4 diseases were under- 
gone by adaptation of reported methods (Table 1) stated 
in Table 1 in samples from patients and control indi- 
viduals. 
Alpha-galactosidase A (GLA): A 3 mm diameter cir- 
cle from DBS filter paper was placed into a well of a 
black microplate and 70 l of the reaction mixture con- 
taining 3.57 mol/l 4-methylumbelliferyl-α-D-galactopy- 
ranoside (Glycosynth, Cheshire, England) and 0.07 mol/l 
N-acetylgalactosamine (Toronto Research Chemicals 
Inc., North York, Ontario, Canada) in 0.15 mol/l acetate 
buffer pH = 4.5 was added. After an incubation for 8 h at 
37˚C, the stop solution (180 l of 1 mol/l ethylenediamine, 
pH = 11.4) was added. 
Beta-glucosidase (BGLU): A 3-mm diameter circle 
from DBS filter paper was placed into a well of a black 
microplate and 150 l of the reaction mixture containing 
4-methylumbelliferyl-β-D-glucopyranoside 10 mmol/l (G- 
lycosynth, Cheshire, England) and sodium taurocholate 
(Sigma, Saint Louis, MO, USA) 50 mmol/l in 0.54 mol/l 
phosphate-citrate buffer pH 5.5 was added. After an in- 
cubation for 24 h at 37˚C, the stop solution (150 l of 0.5 
mol/l glycine-NaOH buffer pH = 10.3) was added. 
Iduronate-2-sulphatase (IDS): A 2-mm diameter circle 
from DBS filter paper was placed into an eppendorf and 
50 l BSA 0.2% was added to elute the blood. 10 l of 
eluted blood in BSA was placed into a well of a black 
microplate and continued as the method reported by 
Voznyi et al. [11]. Briefly, 20 l of 4-Methylumbellifer- 
yl--iduronato-2-sulfato 1.25 mM (Moscerdam substra- 
tes, Oegstgeest, the Netherlands) in 0.1 M sodium ace- 
tate pH = 5 containing 10mM lead acetate was added. 
After an incubation for 24 h at 37˚C, 20 l of 0.05 M cit- 
rate-phosphate pH = 4.5 buffer and 10 l of alfa-iduroni- 
dase purified from bovine testis (Moscerdam substrates, 
Oegstgeest, the Netherlands) were added. After an incu- 
bation for 24 h at 37˚C, the stop solution (150 l of 0.5 
mol/l sodium carbonate/bicarbonate pH = 10.7 buffer) 
was added. 
 
Table 1. List of the enzymes, abbrevations and bibliographic references of the enzyme assays methods. 
Disease Enzyme Enzyme abbreviation Enzyme Classification number Reference 
Fabry Alpha-galactosidase A GLA EC 3.2.1.22 [6] 
Gaucher Beta-D-glucosidase BGLU EC 3.2.1.45 [10] 
Hunter Iduronate-2-sulfatase IDS EC 3.1.6.13 [11] 
Maroteaux Lamy Arylsulfatase B ASB EC 3.1.6.12 [8] 
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Arylsulphatase B (ASB): A 2-mm diameter circle 
from DBS filter paper was placed into a well of a black 
microplate and 150 l of the reaction mixture containing 
15 m mol/l lead acetate and 10 mmol/l 4-methylum- 
belliferyl-sulfate (Glycosynth, Cheshire, England) in 15 
mmol/l acetate buffer pH = 5.0. After incubation for 24 h 
at 37˚C with agitation, the stop solution (150 ml of 0.085 
mol/l glycine-NaOH buffer pH 10.5) was added. 
In all cases, the fluorescence of the product (excitation 
365 nm; emission 450 nm) was measured on a Twinkle 
LB 970 fluorometer (Berthold Technologies, Bad Wild- 
bad, Germany). A standard curve of 4-methylumbelli- 
ferone (Sigma, Saint Louis, MO, USA) was used to ex- 
trapolate fluorescence counts to moles of enzymatic 
product. The enzymatic activity was expressed as mi- 
cromoles of 4-methylumbelliferone produced per liter of 
blood per hour. 
2.3. Analitical Parameters 
Sensitivity, specificity, positive (PPV) and negative 
(NPV) predictive values and positive results proportion for 
each of the 4 enzymatic methods for diagnosis of Fabry, 
Gaucher, Hunter and Maroteaux-Lamy were calculated. 
3. RESULTS 
Each sample was assayed in duplicate. One blank was 
included for each sample, consisted of addition of both 
substrate and stop solutions at the same time at the end 
of the incubation time. Appropriate incubation times for 
each enzyme were chosen, among the linearity curve, in 
order to obtain enough 4-MU to be detected by the 
fluorometer and in comparison to the counts of the blank. 
Intra-assay CVs were below 9% and inter-assay CVs 
below 15% for all the enzymes. 
Histogram of enzymatic activity of GLA, BGLU, IDS 
and ASB from patients and normal control individuals is 
shown in Figure 1. The analytical parameters calculated 
for each of the methods is shown in Table 2. 
3.1. GLA 
Histogram of enzymatic activity of GLA from hemyzy- 
gous, heterozygous and normal control individuals is 
shown in Figure 1(a). Mean value of GLA from normal 
controls was 6.12 ± 2.28 moles/l·h, and the cut-off 
(mean - 2SD) was 1.56. As shown in Figure 1(a), there 
is no overlap between the values from normal controls 
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Figure 1. Histograms and individuals values, respectively, of enzymatic activity determination in DBS for diagnosis of Fabry (1(a) 
and 1(b)), Gaucher (1(c) and 1(d)), Hunter (1(e) and 1(f)), and Maroteaux-Lamy (1(g) and 1(h)) diseases. 
 
Table 2. Analytical parameters for the enzymatic activity de-
termination in DBS for diagnosis of Fabry, Gaucher, Hunter 
and Maroteaux-Lamy diseases. 
 Fabry Gaucher Hunter Maroteaux Lamy
Sensitivity 100 97 100 100 
Specificity 100 100 100 100 
VPP 100 100 100 100 
VPN 100 99 100 100 
Positive results (%) 100 99 100 100 
 
and male patients, giving a sensitivity and specificity of 
100%. Moreover both predictive values are 100% (Table 
2). Values from heterozygous females with Fabry disease, 
showed a high variability, ranging from very low values 
to normal ones. 
3.2. BGLU 
Histogram of values of BGLU enzymatic activity in pa- 
tients and normal controls revealed a minimal (but pre-
sent) overlap between both groups (Figure 1(c)). Cut- 
off value of BGLU enzymatic activity is 1.87 μmoles/l.h. 
As can be seen in Figure 1(d), one confirmed Gaucher 
patient exhibited an enzymatic activity value coincident 
with the cut-off value of this enzymatic assay. This result 
reduces the sensitivity of this method to 97%. However, 
the specificity was 100%. 
We carried out a parallel analysis of BGLU in leuko-
cytes and DBS of samples from patients belonging to the 
3 groups. The results are shown in Figure 2. Samples 
from a few normal controls and heterozygotes on DBS 
revealed enzyme values close to or at the cut-off value; 
however, the respective value in leukocyte is above its 
cut-off. Moreover, a homozygous patient with a DBS 
value close to cut-off, showed very low enzymatic activ-
ity in leukocyte homogenates. 
3.3. IDS 
IDS enzymatic activity values obtained from Hunter pa-
tients and normal individuals showed no overlap between 
both groups, with a good separation (Figures 1(e) and (f)). 
All analytical parameters of this method were 100%. 
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Figure 2. Direct comparison of enzyme measurements from 
DBS and leukocytes from Gacuher homozygotes, hetero- 
zygotes and normal control patients. 
 
Samples from heterozygous showed intermediate numbers. 
3.4. ASB 
Cut-off value as determined by this method was 2.28 
moles/l.h. Enzymatic activity of ASB in DBS (Figures 
1(g) and (h)) from all the homozygous patients with 
MPS VI showed values below the cut-off. Analytical 
parameters were 100%. 
3.5. Stability of Samples at Room Temperature 
Stability of the samples stored at room temperature 
(20˚C - 25˚C) for different days was analyzed (Figure 3). 
The observed enzyme activities of GLA, BGLU and IDS 
show little changes, even at 60 days. Regarding ASB 
activity, a small, but continuous reduction of enzyme 
activity is revealed up to 60 days. However, the reduc-
tion is no more than 15%, and this reduction would no 
modify the final diagnosis. 
4. Discussion 
After clinical suspicion of LSD enzymatic activity deter-
mination of lysosomal enzymes is traditionally under-
gonein leukocytes isolated from 10 ml of blood or fibro-
blasts culture. Diagnosis of lysosomal storage disorders in 
DBS on filter paper was introduced in 2001 [6] as a 
method with several advantages over testing in leuko-
cytes. One of the main advantages is the possibility to 
mail the DBS samples to specialized laboratories by 
ordinary mail at room temperature. The cost of shipment 
 
 
Figure 3. Evaluation of stability of the samples stored at room temperature for different days. The result is ex-
pressed as the ratio (%) between the activity determined at each time point to reference activity (day 0). 
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is rather low and accessible, and there is no need for 
special conditions of temperature at transport, nor strict 
limitations on time of shipment, nor need for customs 
importation documents. Time and cost needed to per-
form an assay are important variables to take into ac-
count when a lab is going to implement a new technique 
and when high amount of samples have to be processed. 
The costs of each assay are directly dependent on the 
cost of the specific reagent for each enzyme to be ana-
lyzed. However, there are no substantial differences in 
the amount of substrate needed for DBS in comparison 
to the determination in leukocytes. When using DBS, 
you avoid the need for isolation and sonication of leu-
kocytes extracts. These processes could take 1 more 
working days. Moreover, due to enzyme activity is ex-
pressed per liter of blood that is dependent on the di-
ameter of the spot; you do not have to determine protein 
concentration. Assays in DBS reduce cost and time. 
Substrates for GLA, BGLU and ASB are produced and 
marketed by a few companies and IDS reagents are 
manufactured by one company. Depending on the coun-
try, in order to acquire the substrates you could have a 
distributor of the reagent, or, you have to import the re-
agents. In the case of import, procedures are dependent 
on each country regulation. In summary, DBS technol-
ogy improves the accessibility of patients to accurate and 
early diagnosis. Access to early diagnosis, at least at the 
time of onset of clinical manifestations would improve 
effectiveness of therapy. Specific enzyme replacement 
therapy is available for each of the 4 diseases, whose 
diagnosis in DBS is evaluated here. 
Civallero et al. [9] evaluated twelve enzyme assays 
for diagnosis of LSD, however they reported a need for 
centrifugation before fluorescence measurement. In our 
work, we incubate the reaction mixture and read the 
fluorescence directly at the microplate, without cen-
trifugation. This means a simplification of the assay. 
Measuring GLA activity in DBS samples resulted in a 
test with 100% sensitivity and specificity for diagnosis of 
male patients with Fabry disease. Female patients with 
Fabry disease revealed variable values, most of them 
above the cut-off level. Similar observations were re- 
ported by Linthorst [12], and even when using leukocytes 
[13]. It is a consequence of random X-inactivation process 
[14] and not a problem of the method itself. Genetic 
analysis should be always included to perform the con-
firmation of diagnosis of females with Fabry disease. This 
DBS method enabled to carry out screening strategies in 
at risk-populations involving large number of male sam-
ples [15,16], with the benefit to detect previously undiag-
nosed Fabry patients, and new Fabry families. 
Development of BGLU enzymatic assay in DBS was 
reported in 2002 [10] using a large cohort of Gaucher 
patients. They did not find any overlap of values be-
tween patients and controls, however nor was cut-off nor 
clinical efficacy parameters determined. We aimed to 
evaluate these parameters in order to be aware of the 
clinical feasibility of this assay. Based on our results, 
determination of activity of BGLU in filter paper could 
be useful as a screening method. Values close to or be- 
low the cut off level should be confirmed by the deter-
mination of BGLU in leukocytes. 
MPS diagnosis starts with clinical recognition of ty- 
pical clinical manifestations such as coarse face, short 
stature, dysostosis multiplex, hepatosplenomegaly, air- 
way and heart disease. Different MPS types and sub- 
types could share the phenotype, and also the type of 
accumulated GAG [17], therefore demonstration of the 
reduction of specific enzymatic activity is the confirma- 
tory diagnosis. Various MPS enzymes could be assay in 
DBS [8,9]. In this study we included the ones for MPS II 
and VI. We found good efficacy of both methods. More- 
over, we analyzed both enzymes (IDS and ASB) in all 
MPS II and VI patients. It is important for differential 
diagnosis with multiple sulfatase deficiency [18,19]. In 
all the cases, the other sulphatase assayed was within the 
range of normal controls (not shown). 
Looking at the histograms obtained, the better separa-
tion between normal control values and hemy/homozy- 
gous ones was observed for IDS activity, followed by 
ASB, then GLA, and the poorest for BGLU. Diagnosis 
of hemy/homozygous patients with Fabry, Hunter and 
Maroteaux-Lamy diseases using DBS samples showed 
ideal parameters of 100% sensitivity and specificity. In 
conclusion, for these 3 disorders, these DBS methods are 
reliable. Specific enzyme analysis in leukocytes of those 
samples from patients who showed reduced values in 
dried blood spots will confirm the diagnosis. 
Stability of samples at room temperature is an impor-
tant issue, taking into account samples should be mailed 
to the reference lab. Time process since obtaining the 
sample to enzyme assay could be, sometimes, of around 
30 days. Looking at the values of stability described here, 
the result would be reliable, in accordance with other 
authors [20]. We would recommend not extending the 
analysis of a sample taken more than 30 days before, 
especially for ASB activity. 
Other methods using DBS have been developed for 
LSD diagnosis. Immunoquantification of enzymes im-
plies the use of specific antibodies, and it is based on 
quantification of the protein, nor the enzyme activity 
[21]. However, a disadvantage of this method is that an- 
tibodies could not be available for every lab. On the 
other hand, MS/MS technology was also used for LSD 
diagnosis in a convenient multiplex assay [22]; the ex-
pensive equipment could be an obstacle for labs from 
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developing countries. Quality control materials to be 
used for every method are being prepared [23], which 
will be used to the development of a quality control sys-
tem to standardize the assays around the different refer-
ence laboratories. 
In conclusion, in this work we analyzed the usefulness 
of DBS samples for diagnosis of 4 LSDs. DBS methods 
for IDS, ASB and GLA activities shown to be reliable, 
however, BGLU DBS assay would need a posterior con-
firmatory step. We recommend evaluating available me- 
thods for other lysosomal diseases diagnosis in DBS, in 
order to evaluate its usefulness as screening and/or con-
firmatory methods. 
5. CONCLUSIONS 
Leukocyte measurement is the only reliable way to di-
agnose Gaucher disease. For Hunter, Fabry and Maro- 
teaux-Lamy disorders discrimination between patients 
and controls seems adequate by DBS.  
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